Abstract
18 chromone derivatives were designed and synthesized from paeonol. All synthetic compounds were evaluated for their anti-proliferative activity towards eight human cancer cell lines including HepG2, HL-60, KB, LLC, LNCaP, LU-1, MCF7, and SW480. Compounds 3g and 3h presented the best cytotoxic effects towards tested cancer cell lines except HepG2. Their IC50 values were ranging from 7.9±0.4 to 18.9±1.3 μg/mL. Meanwhile, compound 3l showed selective cytotoxicity against MCF7 and KB with IC50 of 13.7±0.6 and 15.5±0.9 μg/mL, respectively.
Keywords: Anti-cancer activity, Imidazolidin-4-one, 7-Methoxychromone, Paeonol, Pyrimidine-2, 4, 6(1H, 3H, 5H)-trione, Semi-synthesis.
Letters in Drug Design & Discovery
Title:Promising Anticancer Drug Candidates Based on the 7-methoxychromone Scaffold: Synthesis and Evaluation of Antiproliferative Activity
Volume: 12 Issue: 5
Author(s): Hoang Le Tuan Anh, Nguyen Thi Cuc, Pham Hai Yen, Nguyen Xuan Nhiem, Bui Huu Tai, Do Thi Thao, Nguyen Hoai Nam, Chau Van Minh, Phan Van Kiem and Young Ho Kim
Affiliation:
Keywords: Anti-cancer activity, Imidazolidin-4-one, 7-Methoxychromone, Paeonol, Pyrimidine-2, 4, 6(1H, 3H, 5H)-trione, Semi-synthesis.
Abstract: 18 chromone derivatives were designed and synthesized from paeonol. All synthetic compounds were evaluated for their anti-proliferative activity towards eight human cancer cell lines including HepG2, HL-60, KB, LLC, LNCaP, LU-1, MCF7, and SW480. Compounds 3g and 3h presented the best cytotoxic effects towards tested cancer cell lines except HepG2. Their IC50 values were ranging from 7.9±0.4 to 18.9±1.3 μg/mL. Meanwhile, compound 3l showed selective cytotoxicity against MCF7 and KB with IC50 of 13.7±0.6 and 15.5±0.9 μg/mL, respectively.
Export Options
About this article
Cite this article as:
Anh Le Tuan Hoang, Cuc Thi Nguyen, Yen Hai Pham, Nhiem Xuan Nguyen, Tai Huu Bui, Thao Thi Do, Nam Hoai Nguyen, Minh Van Chau, Kiem Van Phan and Kim Ho Young, Promising Anticancer Drug Candidates Based on the 7-methoxychromone Scaffold: Synthesis and Evaluation of Antiproliferative Activity, Letters in Drug Design & Discovery 2015; 12 (5) . https://dx.doi.org/10.2174/1570180812666141111235539
DOI https://dx.doi.org/10.2174/1570180812666141111235539 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of TGF- β in the Tumor Stroma
Current Cancer Drug Targets Structure-Activity Relationships of Glutamate Carboxypeptidase II (GCPII) Inhibitors
Current Medicinal Chemistry Treatment of Antipsychotic-Induced Hyperprolactinemia: An Update on the Role of the Dopaminergic Receptors D2 Partial Agonist Aripiprazole
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery A Survey of Prostate Segmentation Techniques in Different Imaging Modalities
Current Medical Imaging The Bioanalytical Molecular Pharmacology of the N-methyl-<sub>D</sub>-Aspartate (NMDA) Receptor Nexus and the Oxygen-Responsive Transcription Factor HIF-1α : Putative Mechanisms and Regulatory Pathways Unravel the Intimate Hypoxia Connection
Current Molecular Pharmacology Rheumatic Manifestations in Malignancy
Current Rheumatology Reviews HLA-I Antigen Presentation and Tapasin Influence Immune Responses Against Malignant Brain Tumors-Considerations for Successful Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry The Finely Regulating Well-defined Functional Polymeric Nanocarriers for Anti-tumor Immunotherapy
Mini-Reviews in Medicinal Chemistry Production of High-purity Radium-223 from Legacy Actinium-Beryllium Neutron Sources
Current Radiopharmaceuticals Current Perspectives on Novel Drug Delivery Systems and Therapies for Management of Prostate Cancer: An Inclusive Review
Current Drug Targets Biological Activity In Vitro of Side-Chain Modified Analogues of Calcitriol
Current Pharmaceutical Design Targeting Telomerase for Cancer Therapy
Current Cancer Therapy Reviews Recent Advances in Small Molecule Prodrugs for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Effect of Some Triterpene Glycosides Applied in vitro on Chromatin State in Human Cells
Current Bioactive Compounds Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets Ligand-Targeted Liposomes for Cancer Treatment
Current Drug Delivery Editorial [Hot topic: Current Topics in the Development of Radioligands for Positron-Emission Tomography Imaging (Guest Editors: Andrew G. Horti and Robert F. Dannals)]
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Emerging Azoles: Structure Function Relationship and Their Therapeutic Potential)
The Natural Products Journal MicroRNA-34a and its target genes: Key factors in cancer multidrug resistance
Current Pharmaceutical Design Polyphenols: Potential Future Arsenals in the Treatment of Diabetes
Current Pharmaceutical Design